Real-World Assessment of Disease Characteristics and Clinical Outcomes in Alopecia Areata in a Global Noninterventional Observational Cohort (ADAAGIO)
March 2024
in “
Skin
”
TLDR Current treatments for alopecia areata often fail to achieve and maintain significant hair regrowth.
This study reviewed 741 patients with alopecia areata (AA) across the UK, France, Spain, and Germany, focusing on those with ≥50% scalp hair loss. The median age at diagnosis was 27 years, and 52.6% were female. The mean baseline Severity of Alopecia Tool (SALT) score was 63.5, and the mean Dermatologic Life Quality Index (DLQI) score was 19.2, indicating a significant impact on quality of life. Common treatments included topical corticosteroids (55.6%), intralesional corticosteroids (22.5%), systemic immunosuppressants (22.0%), and minoxidil. Despite a mean SALT score reduction of -44.6% at 12 months, 90.1% of patients did not achieve a sustained SALT score of ≤20. The study concludes that current treatments may be suboptimal in achieving and maintaining significant clinical improvement in AA patients.